Author

Geert R. D'Haens

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB
EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

Geert R. D'Haens  et al.

NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY
NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY

Geert R. D'Haens  et al.

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION
LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

Geert R. D'Haens  et al.

UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Geert R. D'Haens  et al.

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Geert R. D'Haens  et al.

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

Geert R. D'Haens  et al.

MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL
MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL

Geert R. D'Haens  et al.

REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE
REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE

Geert R. D'Haens  et al.

HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB
HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB

Geert R. D'Haens  et al.

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Geert R. D'Haens  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Geert R. D'Haens  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

Geert R. D'Haens  et al.

RESPONSE TO TOFACITINIB IN ULCERATIVE COLITIS PREDICTED BY A MACHINE-LEARNING ALGORITHM; A MULTI-OMICS APPROACH
RESPONSE TO TOFACITINIB IN ULCERATIVE COLITIS PREDICTED BY A MACHINE-LEARNING ALGORITHM; A MULTI-OMICS APPROACH

Geert R. D'Haens  et al.

DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH

Geert R. D'Haens  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Geert R. D'Haens  et al.

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2
A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

Geert R. D'Haens  et al.

Item 81 - 98 / 98
1 2 3 4
5